Almirall S.A. (ALM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Almirall S.A. (ALM) has a cash flow conversion efficiency ratio of 0.060x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€88.75 Million ≈ $103.76 Million USD) by net assets (€1.48 Billion ≈ $1.72 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Almirall S.A. market capitalisation for the company's overall valuation and market capitalisation.
Almirall S.A. - Cash Flow Conversion Efficiency Trend (2005–2024)
This chart illustrates how Almirall S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Almirall S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Almirall S.A. ranked by their cash flow conversion efficiency. Explore earnings quality score of Almirall S.A. to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Procter & Gamble Hygiene and Health Care Limited
NSE:PGHH
|
0.688x |
|
Konecranes Plc
HE:KCR
|
0.066x |
|
CarGurus
NASDAQ:CARG
|
0.622x |
|
Shufersal
TA:SAE
|
0.144x |
|
Anhui Jingcheng Copper Share Co Ltd
SHE:002171
|
-0.009x |
|
Bombardier Inc
TO:BBD-A
|
-1.613x |
|
Wanda Cinema Line Corp
SHE:002739
|
0.065x |
|
Ansell Limited
F:PD1A
|
0.031x |
Annual Cash Flow Conversion Efficiency for Almirall S.A. (2005–2024)
The table below shows the annual cash flow conversion efficiency of Almirall S.A. from 2005 to 2024. View ALM stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €1.49 Billion ≈ $1.74 Billion |
€160.77 Million ≈ $187.95 Million |
0.108x | +69.08% |
| 2023-12-31 | €1.46 Billion ≈ $1.71 Billion |
€93.48 Million ≈ $109.29 Million |
0.064x | -45.69% |
| 2022-12-31 | €1.32 Billion ≈ $1.54 Billion |
€155.10 Million ≈ $181.33 Million |
0.118x | -35.32% |
| 2021-12-31 | €1.29 Billion ≈ $1.50 Billion |
€233.85 Million ≈ $273.40 Million |
0.182x | +43.80% |
| 2020-12-31 | €1.30 Billion ≈ $1.52 Billion |
€164.76 Million ≈ $192.63 Million |
0.126x | -41.38% |
| 2019-12-31 | €1.28 Billion ≈ $1.50 Billion |
€276.15 Million ≈ $322.84 Million |
0.216x | +79.51% |
| 2018-12-31 | €1.19 Billion ≈ $1.39 Billion |
€143.21 Million ≈ $167.43 Million |
0.120x | +2135.49% |
| 2017-12-31 | €1.13 Billion ≈ $1.33 Billion |
€6.09 Million ≈ $7.12 Million |
0.005x | -92.22% |
| 2016-12-31 | €1.52 Billion ≈ $1.78 Billion |
€105.06 Million ≈ $122.82 Million |
0.069x | -40.86% |
| 2015-12-31 | €1.46 Billion ≈ $1.71 Billion |
€170.88 Million ≈ $199.78 Million |
0.117x | -75.81% |
| 2014-12-31 | €1.34 Billion ≈ $1.57 Billion |
€646.93 Million ≈ $756.34 Million |
0.483x | +539.23% |
| 2013-12-31 | €888.33 Million ≈ $1.04 Billion |
€67.11 Million ≈ $78.46 Million |
0.076x | -38.11% |
| 2012-12-31 | €923.67 Million ≈ $1.08 Billion |
€112.75 Million ≈ $131.82 Million |
0.122x | +4.19% |
| 2011-12-31 | €854.71 Million ≈ $999.25 Million |
€100.14 Million ≈ $117.07 Million |
0.117x | -45.02% |
| 2010-12-31 | €819.30 Million ≈ $957.85 Million |
€174.60 Million ≈ $204.13 Million |
0.213x | -38.82% |
| 2009-12-31 | €751.00 Million ≈ $878.00 Million |
€261.60 Million ≈ $305.84 Million |
0.348x | -- |
| 2008-12-31 | €0.00 ≈ $0.00 |
€233.10 Million ≈ $272.52 Million |
x | -- |
| 2007-12-31 | €573.65 Million ≈ $670.66 Million |
€179.03 Million ≈ $209.31 Million |
0.312x | +45.16% |
| 2006-12-31 | €763.21 Million ≈ $892.28 Million |
€164.09 Million ≈ $191.84 Million |
0.215x | +36.46% |
| 2005-12-31 | €898.52 Million ≈ $1.05 Billion |
€141.57 Million ≈ $165.51 Million |
0.158x | -- |
About Almirall S.A.
Almirall, S.A. operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising Psoriasis, atopic dermatitis, acne, actinic keratosis, onychomycosis, androgenic alopecia, oncodermatology, and orphan indications, as well as for alimentary tract and metabolism; antiinfecti… Read more